TABLE 4.
Percentage of use of different treatment strategies for peri‐implantitis by respondent group
| Oral hygiene related treatment | Who? | 1 a | 2 | 3 | 4 | 5 | Mean ± SD, P value |
|---|---|---|---|---|---|---|---|
| ‐ Educating the patient about oral hygiene | U.S. | 0.0% | 1.3% | 1.8% | 7.0% | 89.9% | 4.86 ± 0.488 |
| Europe | 0.0% | 0.0% | 0.0% | 5.1% | 94.9% |
4.95 ± 0.220 0.005 |
|
| ‐ Plaque control | U.S. | 0.0% | 1.0% | 1.6% | 7.0% | 90.4% | 4.87 ± 0.456 |
| Europe | 0.0% | 0.0% | 0.0% | 7.1% | 92.9% |
4.93 ± 0.258 0.080 |
|
|
Oral hygiene treatment index b (alpha = 0.97) |
U.S . | Mean = 4.86 | SD = 0.467 | P = 0.020 | |||
| Europe | Mean = 4.93 | SD = 0.228 | |||||
| Non‐surgical and regenerative treatment | Who? | 1 1 | 2 | 3 | 4 | 5 |
Mean ± SD, P value |
| ‐ Mechanical debridement | U.S. | 0.3% | 0.8% | 3.4% | 13.2% | 82.4% | 4.77 ± 0.570 |
| Europe | 7.4% | 4.3% | 12.8% | 14.9% | 60.6% |
4.17 ± 1.250 < 0.001 |
|
| ‐ Antiseptic cleansing | U.S. | 2.4% | 5.0% | 13.9% | 22.8% | 56.0% | 4.25 ± 1.024 |
| Europe | 5.1% | 5.1% | 19.2% | 22.2% | 48.5% |
4.04 ± 1.160 0.077 |
|
| ‐ Local/systemic antibiotic therapy | U.S. | 3.1% | 8.3% | 21.9% | 31.0% | 35.7% | 3.88 ± 1.085 |
| Europe | 7.1% | 26.3% | 27.3% | 31.3% | 8.1% |
3.07 ± 1.090 < 0.001 |
|
| ‐ Regeneration | U.S. | 4.0% | 10.1% | 30.9% | 35.2% | 19.7% | 3.57 ± 1.042 |
| Europe | 15.3% | 33.3% | 33.3% | 16.7% | 1.4% |
2.56 ± 0.991 < 0.001 |
|
| ‐ Autogenous bone graft | U.S. | 32.3% | 24.7% | 19.9% | 16.3% | 6.7% | 2.40 ± 1.274 |
| Europe | 38.9% | 26.3% | 23.2% | 8.4% | 3.2% |
2.11 ± 1.115 0.026 |
|
| ‐ Allograft | U.S. | 9.6% | 10.7% | 26.0% | 39.1% | 14.8% | 3.39 ± 1.150 |
| Europe | 38.9% | 21.1% | 28.4% | 10.5% | 1.1% |
2.14 ± 1.088 < 0.001 |
|
| ‐ Xenograft | U.S. | 31.7% | 15.9% | 19.8% | 24.4% | 8.2% | 2.61 ± 1.363 |
| Europe | 29.0% | 25.8% | 29.0% | 14.0% | 2.2% |
2.34 ± 1.108 0.048 |
|
| Regenerative treatment | Who? | 1 a | 2 | 3 | 4 | 5 |
Mean ± SD, P value |
| ‐ GTR with a membrane | U.S. | 7.7% | 11.6% | 25.1% | 40.7% | 14.8% | 3.43 ± 1.113 |
| Europe | 27.7% | 21.3% | 28.7% | 19.1% | 3.2% |
2.49 ± 1.180 < 0.001 |
|
| Non‐surgical and regenerative treatment index b (alpha = 0.79) | U.S . | Mean = 3.05 | SD = 0.848 | P < 0.001 | |||
| Europe | Mean = 2.27 | SD = 0.824 | |||||
| Single items | Who? | 1 1 | 2 | 3 | 4 | 5 |
Mean ± SD, P value |
| ‐ Alloplast | U.S. | 64.5% | 14.5% | 11.0% | 7.0% | 2.9% | 1.69 ± 1.098 |
| Europe | 56.3% | 21.1% | 15.5% | 5.6% | 1.4% |
1.75 ± 1.010 0.699 |
|
| ‐ Resective surgery | U.S. | 10.6% | 16.4% | 34.1% | 31.2% | 7.7% | 3.09 ± 1.096 |
| Europe | 5.2% | 13.5% | 19.8% | 45.8% | 15.6% |
3.53 ± 1.076 < 0.001 |
|
| ‐ Implantoplasty | U.S. | 19.6% | 26.9% | 25.3% | 21.0% | 7.3% | 2.69 ± 1.210 |
| Europe | 25.6% | 20.0% | 17.8% | 26.7% | 10.0% |
2.76 ± 1.360 0.693 |
|
| ‐ Laser systems | U.S. | 55.9% | 11.6% | 9.6% | 11.6% | 11.3% | 2.11 ± 1.459 |
| Europe | 72.0% | 8.6% | 7.5% | 3.2% | 8.6% |
1.68 ± 1.270 0.005 |
|
| ‐ Photodynamic therapy | U.S. | 81.1% | 9.5% | 6.0% | 3.2% | 0.3% | 1.32 ± 0.751 |
| Europe | 75.0% | 13.0% | 5.4% | 3.3% | 3.3% |
1.47 ± 0.977 0.184 |
|
Legend:
The answers to the question “How often do you use the following treatment strategies when you treat a patient with peri‐implantitis?” ranged from “1” = “never” to 5 = “always”.
Indices were computed by averaging the responses loading on the respective factor for which an index was created.